LQDA is tracked by BiotechSign with a current catalyst score of 61/100 and grade C. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Liquidia Technologies (LQDA) has a BiotechSign Catalyst Score of 61/100, rated C. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Liquidia Technologies (LQDA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT04691154[3] evaluates L606 inhalation suspension in Pulmonary Arterial Hypertension with a target enrollment of 28 participants. Trial NCT03992755[4] evaluates LIQ861 Inhaled Treprostinil in Primary Pulmonary Hypertension with a target enrollment of 92 participants.
LQDA has 5 Form 4 insider filings recorded at the SEC in the past 30 days[5].